Biological therapy of autoimmune blistering diseases. (1st February 2019)

• Record Type: Journal Article
• Authors: Alaibac, Mauro
• Is Part Of: Expert opinion on biological therapy. Volume 19:Number 2(2019)
• Page Start: 149
• Page End: 156
• Publication Date: 2019-02-01
• Subjects: Autoimmune blistering diseases -- pemphigus vulgaris -- pemphigoid -- biological agents -- autoimmunity; Gene therapy -- Periodicals; Protein drugs -- Periodicals; Peptide drugs -- Periodicals; Immunotherapy -- Periodicals; Drug delivery systems -- Periodicals; 615.5
• DOI: 10.1080/14712598.2019.1559291
• Languages: English
• ISSNs: 1471-2598

Abstract

ABSTRACT: Introduction : Autoimmune blistering skin diseases are a group of disorders subdivided according to the location of blister formation: intraepidermal blistering in the pemphigus group and subepidermal in the pemphigoid group. These conditions are clinically heterogeneous and are treated with systemic corticosteroids and/or other forms of immunosuppression on the basis of clinical subtype and disease severity. These approaches may not be effective for the induction and maintenance of clinical response or need to be stopped because of intolerable side effects. Areas covered : Biological therapies can represent a valid alternative strategy in various autoimmune blistering disorders and this review article will address this issue with a special focus on pemphigus vulgaris and bullous pemphigoid. These biological approaches are designed to target B cells, autoantibodies, complement proteins, and several cytokines. Expert opinion : Innovative strategies for the treatment of autoimmune blistering conditions primarily depend on the use of drugs with a high degree of specificity targeting crucial steps in the immunopathology of these disorders. Novel biological agents offer treatment alternatives to patients with autoimmune blistering conditions by targeting B cells, pathogenic autoantibodies, complement and cytokines.